Impact of COVID-19 in patients with multiple myeloma based on a global data network

J. Martinez-Lopez, G. Hernandez-Ibarburu, R. Alonso, J. M. Sanchez-Pina, I. Zamanillo, N. Lopez-Munoz, Rodrigo Iniguez, C. Cuellar, M. Calbacho, M. L. Paciello, R. Ayala, N. Garcia-Barrio, D. Perez-Rey, L. Meloni, J. Cruz, M. Pedrera-Jimenez, P. Serrano-Balazote and J. de la Cruz

© The Author(s) 2021

The COVID-19 pandemic has represented a major cause of morbidity/mortality worldwide, overstressing health systems. Multiple myeloma (MM) patients show an increased risk for infections and they are expected to be particularly vulnerable to SARS-CoV-2 infection. Here we have obtained a comprehensive picture of the impact of COVID-19 in MM patients on a local and a global scale using a federated data research network (TriNetX) that provided access to Electronic Medical Records (EMR) from Health Care Organizations (HCO) all over the world. Through propensity score matched analyses we found that the number of new diagnoses of MM was reduced in 2020 compared to 2019 (RR 0.86, 95%CI 0.76–0.96) and the survival of newly diagnosed MM cases decreased similarly (HR 0.61, 0.38–0.81). MM patients showed higher risk of SARS-CoV-2 infection (RR 2.09, 1.58–2.76) and a higher excess mortality in 2020 (difference in excess mortality 9%, 4.4–13.2) than non-MM patients. By interrogating large EMR datasets from HCO in Europe and globally, we confirmed that MM patients have been more severely impacted by COVID-19 pandemic than non-MM patients. This study highlights the necessity of extending preventive measures worldwide to protect vulnerable patients from SARS-CoV-2 infection by promoting social distancing and an intensive vaccination strategies.

Blood Cancer Journal (2021) 11:198; https://doi.org/10.1038/s41408-021-00588-z

INTRODUCTION

Since its outbreak at the end of 2019, the coronavirus disease 2019 (COVID-19) has overstretched National Health Systems (NHS) worldwide and had a profound impact on healthcare quality and access [1–3]. The excess mortality of 2020 compared to the previous years observed in many countries has been attributed to COVID-19 [4, 5], whose effects have been particularly devastating in the oncologic population [6–12].

Multiple myeloma (MM) patients are known to have variable degrees of multifactorial immunodeficiency related to the disease itself and the administered therapies. Therefore the risk of infection is increased in MM patients, and it is a major cause of morbidity and mortality [13–16]. In particular, recent studies have shown that viruses represent a frequent etiology of infections in MM patients [17, 18]. Multicenter and international clinical studies have documented that patients with MM are a vulnerable population at high risk of hospitalization and death following a COVID-19 infection [19–23]. However, there are no data evaluating whether MM patients specifically are at increased risk of infection by SARS-CoV-2 compared with the overall population.

We hypothesized that the COVID-19 pandemic might have decreased or delayed the diagnosis of MM for many patients, in comparison with the pre-COVID-19 era [24, 25], in the context of overburdened NHS, movement restrictions, and other measures implemented to control the spread of the infection. Additionally, we tried to confirm that MM patients were disproportionately impacted by COVID-19 compared with non-MM patients in terms of incidence of COVID-19 infection and survival outcomes.

Since geographical differences may exist between countries such as the incidence of COVID-19, the organization of healthcare delivery, the availability of health resources, the government strategy to combat the pandemic, and many other factors, it seemed appropriate to draw on a global data network to obtain a more accurate and comprehensive picture of the impact of COVID-19 in MM patients. Large network data platforms based on electronic medical records (EMRs) provide capabilities for comparing cohorts across time periods and clinical profiles. For this study, we used TriNetX, a global health research network, to test our hypothesis in an attempt to overcome some of the constraints of previous studies which used local or regional data sources. This platform has previously been shown to be a useful tool for answering research questions in different settings of diseases [26–30].

Thus, the general objective of this study was to provide comparative data on a local, regional and global scale on the impact of COVID-19 on MM patients. The specific aims of our study were to compare the occurrence of new MM diagnoses and the survival of MM patients in 2020 and 2019, and to compare the proportion of COVID-19 cases and the excess mortality in MM and non-MM patients.

Hematology Department, Hospital 12 de Octubre, Complutense University, CNIO, Madrid, Spain. Biomedical Informatics Group, Universidad Politecnica de Madrid, Madrid, Spain. Data Science Group, Hospital 12 de Octubre, Madrid, Spain. TriNetX, LLC, Cambridge, MA, USA. Research Institute imas12, Hospital 12 de Octubre, Madrid, Spain. These authors contributed equally: J Martinez-Lopez, G Hernandez-Ibarburu, R Alonso. email: jmarti01@ucm.es

Received: 27 October 2021 Revised: 18 November 2021 Accepted: 23 November 2021
Published online: 10 December 2021
METHODS

Database network and patients selection

This study was conducted with data obtained from TriNetX, LLC (“TriNetX”) a global federated health research network that provides access to EMRs from healthcare organizations (“HCOs”) all over the world. TriNetX provides access to data containing diagnoses, procedures, medications, laboratory values, genomic information from approximately 90 000 MM patients from over 66 HCOs from the 68 that are part of the network. The analyses were conducted utilizing three networks to confirm our hypotheses: the Hospital 12 de Octubre network (H12O), with 930 000 patients; the TriNetX EMEA Collaborative Network (“EMEA”), with 9,800,000 patients from 15 HCOs (including Hospital 12 de Octubre); and the TriNetX Global Collaborative Network (“Global”), with 82 000 000 patients from 68 Healthcare Organizations (including EMEA HCOs). All data collection, processing, and transmission were performed in compliance with all Data Protection laws applicable to the contributing HCOs, including the EU Data Protection Law Regulation 2016/679, the General Data Protection Regulation on the protection of personal persons with regard to the processing of personal data and the Health Insurance Portability and Accountability Act (“HIPAA”), the US federal law which protects the privacy and security of healthcare data. The TriNetX EMEA and Global Collaborative Networks are distributed networks, and analytics are performed on anonymized or pseudonymized/de-identified (per HIPAA) data housed at the HCOs, with only aggregate results being returned to the TriNetX platform. Individual personal data does not leave the HCOs. As part of the platform, a certified and maintains a robust IT security program that protects both personal data and health care data.

MM patients were identified by the presence of the parent ICD-10-CM code for MM (C90.0) or any of the specific codes (C90.00, C90.01 and C90.02) in their EMR. In addition, we included patients whose MM was miscoded initially as monoclonal gammapathy by identifying patients who had the diagnosis code D47.2 (monoclonal gammapathy) and had been treated with one of the following MM treatments: thalidomide, bortezomib, lenalidomide, daratumumab, melphalan, ixazomib or carfilzomib. For the overall survival analysis, the first day of MM was either the diagnosis or the start of the treatment, whatever happened first. The infection of COVID-19 was identified as either a positive PCR test or an ICD-10-CM diagnosis of COVID-19 in 2020. ICD codes U07.1 (COVID-19, Virus identified), U07.2 (COVID-19, Virus not identified), or U07.9 (Other coronaviruses as the cause of diseases classified elsewhere). Finally, included patients were ≥25 years old.

Patient flowchart and characteristics

A total of 855 patients with MM criteria were identified in H12O network, 7265 in EMEA, and 83,550 in Global. Control cohorts of non-MM patients were identified by propensity score matching 1:1 on age and gender from a pool of individuals without any diagnoses of MM or monoclonal gammapathy and without any record of receipt of MM treatments (Table 1). For the non-MM patients, the cohort was limited to patients that had a hospital visit in the last 5 years. The three networks were treated with a significantly higher probability of diabetes mellitus, other disorders, and low mean value of glomerular filtration rate (MDRD) compared with non-MM patients. In addition, a significantly higher percentage of MM patients in the global cohort had ischemic heart diseases.

The MM cohort in each of the networks was further stratified to run the different analyses. One set of sub-cohorts included the patients with a new diagnosis of MM from 2019Q1 to 2021Q2 (Fig. 1A). They were used to evaluate the impact of the COVID-19 pandemic in the number of new MM diagnoses (Fig. 2) and in the overall survival (OS) of newly diagnosed MM patients (Fig. 3). Another set of sub-cohorts included MM and non-MM patients that had an emergency visit or hospitalization in 2019 or 2020 (Fig. 1B); they were used to assess the incidence of COVID-19 and the excess mortality in 2020. A third set of cohorts was built with COVID-19 patients, MM and non-MM, to analyse the evolution of the OS in the period of January to May, 2020 compared to the period of June to December 2020 (Fig. 1C). In all settings, non-MM cohorts included patients with sufficient information in their EMR to run the analysis: patients without any diagnosis or with an EMR trajectory shorter than 3 months were excluded.

Statistical analysis

All analyses were generated with TriNetX platform software (TriNetX, Cambridge, MA) in August of 2021 [31]. We compared the incidence (new cases) of MM diagnosis and the survival of MM patients in 2020 and 2019. We also compared the incidence (case count) of COVID-19 and the excess mortality of MM and non-MM patients. Finally, we compared the survival of COVID-19 MM and non-MM cases over two time periods in 2020. The number of new cases of MM and of COVID-19 cases were compared with risk ratios and 95% confidence intervals (95% CI). Kaplan-Meier analysis was used to estimate survival probabilities, and the difference between groups was tested using the log-rank test and quantified with hazard ratios (95% CI), calculated with TriNetX Analytics features. All the cohorts were propensity score-matched on age and gender. For the survival analysis of MM and non-MM patients and the comparisons between 2020 and 2019, the cohorts were also matched on mortality risk factors for COVID-19 patients: I10-I16 (Hypertensive diseases), E08-E13 (Diabetes mellitus), N18 (Chronic kidney disease), I30-I52 (Other forms of heart disease), M00-M99 (Diseases of the musculoskeletal system and connective tissue), J40-J47 (Chronic lower respiratory diseases) and I20-I25 (Ischemic heart diseases) [32-34]. Global was not used in the survival analysis because of network data limitations on out-of-hospital mortality.

RESULTS

New diagnosis of MM cases over time

The total number of new MM patients between 2019Q1 and 2021Q2 was 159 in H12O, 1 297 in EMEA and 12 033 in Global network (Fig. 2). The number of new MM diagnoses was lower in 2020 than in 2019: in H12O, 35 cases vs 63 with a risk ratio (RR) of 0.87 (95% CI 0.62–1.24), p = 0.44; EMEA, 504 vs 589, RR = 0.86 (0.76–0.96), p = 0.008; and Global network, 4670 vs 5357, RR = 0.87 (0.84–0.91), p < 0.001.

COVID-19 cases in MM and non-MM patients

Then, we analyzed patients that had a hospital visit in 2019 to assess if MM patients had a higher incidence of COVID-19 than subjects without diagnosis of MM. After propensity score matching, the H12O cohort had a total number of 417 patients, mean age of 67.4 years and 196 (47%) males; EMEA had a total number of 3738 patients, mean age of 69.4 and 2119 (57%) males, and Global had a total number of 43 192 patients, mean age of 66.5 and 22 819 (52%) males. In the three cohorts, the likelihood of being diagnosed with COVID-19 was higher in MM than in non-MM patients: 38 (9.11%) vs 29 (6.95%), risk ratio 1.31 (0.82–2.08), p = 0.25 with H12O data; 148 (3.96%) vs 71 (1.90%), risk ratio 2.09 (1.58–2.70), p < 0.001 with EMEA network; and 2 018 (4.67%) vs 1174 (2.71%), risk ratio 1.72 (1.60–1.85) p < 0.001 with Global network.

COVID-19 impact on survival of MM patients

We also explored the impact of COVID-19 in the survival of newly diagnosed MM patients in H12O and EMEA networks. Patients newly diagnosed with MM in 2019 (MM 2019) were propensity score matched with patients diagnosed in 2020 (MM 2020) on age and gender. After the matching, each cohort had 56 patients, mean age of 67 and a male proportion of 57.90% (MM 2019) and 60.93% (MM 2020) in EMEA. Patients diagnosed in 2019 had a higher survival probability one year after the diagnosis than patients diagnosed in 2020: H12O, 82.46% (46) vs 73.68%, (41) hazard ratio 0.64 (0.29, 1.43), p = 0.27; EMEA, 87.38% (651) vs 84.50% (628), hazard ratio 0.86 (0.76–0.96), p = 0.008; and Global network, 4670 vs 5357, RR = 0.87 (0.84–0.91), p < 0.001.

We then estimated the excess mortality (2020 vs 2019) in MM and non-MM patients. The balanced cohorts in H12O included 192 MM patients with a 2020 excess mortality of 41%: 32 (16.67%) from the 2019 cohort and 45 (23.44%) from 2020 died. The H12O non-MM balanced cohorts included 134,344 patients with a 2020 excess mortality of 27%: 3797 (2.83%) died within a year after an emergency or hospitalization visit in 2019 while 4 808 (3.58%) died...
Table 1. Characteristics of Multiple Myeloma (MM) cohorts in H12O, EMEA and Global data networks, compared with non-MM cohorts before and after propensity score matching (PSM) on age and gender.

### Demographics

| Cohort | Characteristic | MM N(%)/mean (STD) | non-MM N(%)/mean (STD) | P value | Standard mean difference** |
|--------|----------------|-------------------|------------------------|---------|---------------------------|
|        | Before PSM     | After PSM         | Before PSM             | After PSM |                            |
| H12O   | Current Age    | 71.26 (12.23)     | 43.06 (25.56)          | 71.26 (12.26) | <0.001 (1.40) 0.99(0)    |
|        | Male           | 442 (51.70%)      | 316,079 (47.77%)      | 443 (51.81%) | 0.021 (0.07) 0.96(0)    |
|        | Female         | 413 (48.30%)      | 345,611 (52.23%)      | 412 (48.19%) | 0.021 (0.07) 0.96 (0)   |
| EMEA   | Current Age    | 73.36 (10.71)     | 50.51 (24.84)          | 73.36 (10.71) | <0.001 (1.19) 1 (0)    |
|        | Male           | 4282 (58.94%)     | 3,021,909 (46.87%)    | 4282 (58.94%) | <0.001 (0.24) 1 (0)    |
|        | Female         | 2983 (41.06%)     | 3,417,237 (53.01%)    | 2983 (41.06%) | <0.001 (0.24) 1 (0)    |
| Global | Current Age    | 69.68 (11.83)     | 57.81 (17.91)         | 69.68 (11.83) | <0.001 (0.78) 1 (0)    |
|        | Male           | 45,803 (54.82%)   | 3,384,316 (43.99%)    | 45,803 (54.82%) | <0.001 (0.21) 1 (0)    |
|        | Female         | 37,350 (44.70%)   | 4,280,887 (55.65%)    | 37,350 (44.70%) | <0.001 (0.22) 1 (0)    |

### Laboratory

| Cohort | Characteristic | MM mean (std) | non-MM mean (std) | p value |
|--------|----------------|---------------|-------------------|---------|
| H12O   | GFR (MDRD)    | 74.13 (39.82) | 77.19 (26.78)     | 0.12    |
|        | Hemoglobin in blood (g/dL) | 11.71 (2.29) | 13.78 (2.09)     | <0.001  |
| EMEA   | GFR (MDRD)    | 68.35 (37.72) | 75.79 (28.78)     | <0.001  |
|        | Hemoglobin in blood (g/dL) | 11.12 (2.26) | 13.00 (2.23)     | <0.001  |
| Global | GFR (MDRD)    | 65.42 (33.80) | 73.29 (27.68)     | <0.001  |
|        | Hemoglobin in blood (g/dL) | 11.24 (2.47) | 12.84 (2.52)     | <0.001  |

### Diagnoses

| Cohort | Characteristic name | MM | non-MM | Risk ratio*** (95% CI) | p value |
|--------|---------------------|----|--------|------------------------|---------|
| H12O   | Hypertension        | 333 (38.95%) | 241 (28.19%) | 1.38 (1.21,1.58) | <0.001  |
|        | Ischemic heart diseases | 80 (9.36%) | 76 (8.89%) | 1.05 (0.78,1.42) | 0.737   |
|        | Other forms of heart disease | 250 (29.24%) | 159 (18.60%) | 1.57 (1.32,1.87) | <0.001  |
|        | Diabetes mellitus   | 132 (15.44%) | 125 (14.62%) | 1.06 (0.84,1.32) | 0.636   |
|        | Chronic kidney disease | 114 (13.33%) | 52 (6.082%) | 2.19 (1.60,3.00) | <0.001  |
|        | Injuries            | 134 (15.673%) | 116 (13.567%) | 1.15 (0.91,1.44) | 0.218   |
|        | Other dorsopathies  | 76 (8.89%) | 49 (5.73%) | 1.61 (1.11,2.33) | 0.012   |
|        | Disorders of bone density and structure | 143 (16.73%) | 42 (4.91%) | 3.41 (2.45,4.74) | <0.001  |
|        | Chronic lower respiratory diseases | 91 (10.64%) | 67 (7.84%) | 1.36 (1.01,1.84) | 0.045   |
| EMEA   | Hypertension        | 2933 (40.37%) | 2339 (32.20%) | 1.25 (1.20,1.31) | <0.001  |
|        | Ischemic heart diseases | 1174 (16.16%) | 1235 (17.00%) | 0.95 (0.88,1.02) | 0.174   |
|        | Other forms of heart disease | 2306 (31.74%) | 1486 (20.45%) | 1.55 (1.47,1.64) | <0.001  |
|        | Diabetes mellitus   | 1097 (15.10%) | 950 (13.08%) | 1.16 (1.07,1.25) | <0.001  |
|        | Chronic kidney disease | 1658 (22.82%) | 465 (6.40%) | 3.57 (3,23,3,93) | <0.001  |
|        | Injuries            | 1125 (15.46%) | 967 (13.287%) | 1.17 (1.07,1.26) | <0.001  |
|        | Other dorsopathies  | 1139 (15.65%) | 414 (5.688%) | 2.75 (2.46,3.06) | <0.001  |
|        | Disorders of bone density and structure | 978 (13.44%) | 222 (3.05%) | 4.41 (3,82,5,08) | <0.001  |
|        | Chronic lower respiratory diseases | 1070 (14.73%) | 823 (11.33%) | 1.30 (1,19,1,42) | <0.001  |
| Global | Hypertension        | 45,193 (54.09%) | 38,144 (45.65%) | 1.19 (1.17,1.20) | <0.001  |
|        | Ischemic heart diseases | 18,146 (21.72%) | 14,505 (17.36%) | 1.25 (1.23,1.28) | <0.001  |
|        | Other forms of heart disease | 36,929 (44.20%) | 22,214 (26.59%) | 1.66 (1.64,1.69) | <0.001  |
|        | Diabetes mellitus   | 19,101 (22.86%) | 17,327 (20.74%) | 1.10 (1.08,1.12) | <0.001  |
|        | Chronic kidney disease | 22,430 (26.85%) | 9372 (11.22%) | 2.39 (2.34,2.45) | <0.001  |
|        | Injuries            | 25,601 (30.64%) | 19,990 (23.92%) | 1.41 (1.38,1.43) | <0.001  |
|        | Other dorsopathies  | 31,534 (37.74%) | 19,502 (23.34%) | 1.62 (1.59,1.64) | <0.001  |
|        | Disorders of bone density and structure | 20,586 (24.64%) | 8626 (10.32%) | 2.39 (2.76,2.92) | <0.001  |
|        | Chronic lower respiratory diseases | 16,925 (20.26%) | 13,625 (16.31%) | 1.24 (1.22,1.27) | <0.001  |

*Subsample of the cohort due to computational limitations.
Fig. 1  Flow chart of the study. A Diagram of the cohorts used for the analysis of newly diagnosed multiple myeloma (MM) cases in 2019 and 2020. B Diagram of the cohorts used for the analysis of COVID-19 cases in MM and non-MM patients. C Diagram of the cohorts used for the COVID-19 analysis of mortality analysis (MM vs non-MM) between the first and the second half of 2020.

Fig. 2  New MM cases by year. New cases of MM by data network, age group and quarters of 2019 (blue), 2020 (orange) and 2021 (gray).
in 2020. In EMEA, balanced cohorts included 1,962 MM patients with an excess mortality of 16%: 287 (14.63%) died within one year after the hospitalization or emergency visit in 2019 and 332 (16.92%) in 2020. In the non-MM cohorts \((n = 946,886)\), excess mortality was 7%: 37,047 (3.91%) died after the 2019 visit and 39,581 (4.18%) after the 2020 visit. Excess mortality in 2020 in both data networks was higher in MM than in non-MM patients: the difference in excess mortality was 14% \((-4.7 \text{ to } 32.6, p = 0.1)\) in H12O and 9% \((4.4 \text{ to } 13.2, p < 0.001)\) in EMEA.

The final analysis compared the survival of COVID-19 MM and non-MM patients diagnosed in two periods, January to May 2020 (first period) and June to December 2020 (second period) (Fig. 1). After balancing cohorts with propensity score matching, the analysis showed no statistically significant differences for the survival of COVID-19 MM patients: in H12O, 84.6% (11) vs 76.9%, (10) hazard ratio 0.62 (0.10 – 3.73), \(p = 0.6\); in EMEA, 72.2% (39) vs 64.8%, (35) hazard ratio 0.73 (0.37 – 1.43), \(p = 0.35\). On the contrary, the survival of COVID-19 non-MM patients increased in the second period: 89.41% (703) vs 96.21% (252), hazard ratio 2.64 (2.29 – 3.05), \(p < 0.001\) in H12O; 88.10% (2059) vs 90.94% (1569), hazard ratio 1.25 (1.17 – 1.34), \(p < 0.001\) in EMEA.

**Discussion**

In this real-world data analysis, we showed that diagnosis of new MM cases has decreased during the COVID-19 pandemic at a local and global level. Similarly, the survival of MM patients has decreased in 2020 compared to 2019. Our analysis suggests that MM patients have a higher risk of contracting SARS-CoV-2 infection than non-MM patient population. We found also that the excess mortality in 2020 was higher for MM patients than for non-MM patients. These results confirmed the remarkable impact of the COVID-19 pandemic in the management and outcomes of MM patients.

The COVID-19 pandemic has overloaded our health systems globally; this resulted in a lack of attention to other pathologies that require very specialized diagnostic and therapeutic tools. Some authors hypothesized that the number of newly diagnosed cancer patients has been reduced during pandemic; however, this is the first time in the MM setting that this fact has been demonstrated in a large international multi-site studies with multi-institutional and multi-national patients [9, 24, 25, 28, 35–37]. Our results could mean that globally around 15% of MM patients have not been diagnosed on time, or they have died because of the severe consequences on our health systems and patients. This is consistent with previous analysis on other cancers [28, 29, 38, 39].

There is little information about whether cancer patients have an increased probability of having COVID-19 [37]. In this large series we have confirmed that the likelihood to be diagnosed of COVID-19 is higher in MM patients that in the general population.

Finally, we observed that the survival of MM patients decreased in 2020 compared to 2019. Furthermore, we confirmed that the excess mortality in 2020 was higher in MM population than in non-cancer population. This reflect, the major impact of COVID-19 pandemic in vulnerable populations such as MM patients.

In contrast to the non-MM population, patients with MM did not show any improvement in survival results during the second period of the pandemic (June to December 2020), once the first wave of infection (which was the most devastating and stressing for hospital systems in most European countries and the USA) had passed. This finding could be partially explained by a reduced effectiveness of current COVID-19 therapies in this vulnerable MM population -clinical trials for COVID-19 treatments often excluded cancer patients. The lack of improvement in MM patients survival may also be related to the continued adaptations of the health care systems during the pandemic situation.

Overall, a reduced incidence of hematological malignancies has been reported during the first wave of the pandemic, as we have observed in our study, and some studies are addressing the increased risk of getting COVID-19 in these populations [28]. Prior works have also noticed, in line with our findings in MM, that other malignancies such as chronic lymphocytic leukemia or acute leukemias also associate a higher risk of SARS-CoV-2 infections

---

| Year | MM 2019 | MM 2020 |
|------|---------|---------|
| Deaths | 4 | 2 | 1 | 3 |
| Patients at risk | 56 | 52 | 50 | 49 |
| Survival | 5 | 4 | 3 | 3 |
| Patients at risk | 56 | 51 | 47 | 44 |

Fig. 3 MM survival by year. A KM plots comparing OS after the first year of MM diagnosis of patients diagnosed in 2019 (purple) and in 2020 (green), with H12O data. B KM plots comparing OS after the first year of MM diagnosis of patients diagnosed in 2019 (purple) and in 2020 (green), with EMEA network.
with fatal complications [40–43]. By contrast, chronic myeloid leukemia patients may have not resulted so affected by the pandemic [44–46]. Interestingly, a decrease in the number of hematology-related diagnostic procedures (bone marrow aspirates, flow cytometry assessments, etc) carried out during pandemic period has been reported [47], which could correlate with our observation of lower number of newly diagnosed MM patients during 2020. Since vaccination against SARS-CoV-2 is less effective in hematological neoplasms, these patients might be at risk even after complete vaccination and a specific management different from the overall population may be required to guarantee a better protection [48–51]. Future studies assessing the efficacy of vaccines against SARS-CoV-2 in each particular hematological malignancy and evaluating the impact of the different therapies in the acquisition of COVID-19 immunity will help to optimize the vaccination strategy [52].

There are some study limitations worth mentioning. First, EMR data is subject to data entry errors and data gap; such as the date of MM diagnosis may not be the actual day of MM diagnosis as it was inferred from the EMR record. Mortality data could be incomplete in some organizations or reported with some delay. We excluded from the survival analysis the data network where out-of-hospital deaths are not tracked consistently. Although data were not centrally curated, H12O MM dedicated datasets were used as a reference for controlling the quality of MM data in all cohorts [19, 20]. One of the strength of this study is the validation of the results in three different data networks around the world that provided very consistent findings for all impact measures. In addition, this study included a large number of patients in the study population of interest contrary to most most MM studies. The large sample size and the use of propensity score matching allowed for more accurate comparisons through controlling for potential factors with clinical and prognostic relevance in an attempt to minimize the risk of bias.

This real-world data global analysis showed that COVID-19 has severely impacted MM patients at different levels. Diagnosis of MM patients was delayed and survival of MM patients was reduced in 2020 compared to 2019. MM patients were more frequently infected with SARS-CoV-2 and had higher excess mortality in 2020 than non-MM patients visiting hospitals. By interrogating large EMR datasets from HCO in Europe and globally, we confirmed that MM patients have been more severely impacted by COVID-19 pandemic than non-MM patients. This study highlights the necessity of extending preventive measures worldwide to protect vulnerable patients from SARS-CoV-2 infection by promoting social distancing and an intensive COVID-19 vaccination strategies.

REFERENCES

1. Alfaro M, et al. National health systems and COVID-19 death toll doubling time. Front Public Health. 2021;9:669038.
2. Winkelmann J, et al. European countries’ responses in ensuring sufficient physical infrastructure and workforce capacity during the first COVID-19 wave. Health Policy. 2021;105:168–8510:00172-X.
3. Coccia M. Preparedness of countries to face covid-19 pandemic crisis: strategic positioning and underlying structural factors to support strategies of prevention of pandemic threats. Environ Res. 2021;203:11678.
4. Dorrucci M, et al. Excess mortality in Italy during the COVID-19 pandemic: assessing the differences between the first and the second wave, year 2020. Front Public Health. 2021;9:669209.
5. Kowall B, et al. Excess mortality due to Covid-19: A comparison of total mortality in 2020 with total mortality in 2016 to 2019 in Germany, Sweden and Spain. PLoS ONE. 2021;16:e0255540.
6. Grivas P, et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol. 2021;32:787. Available from: https://pubmed.ncbi.nlm.nih.gov/33746047/.
7. Kuderer NM, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907–1918.
8. Lee LYW, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020;21:1309–1316.
9. Balogun OD, Bea VJ, Phillips E. Disparities in cancer outcomes due to COVID-19-A tale of 2 cities. JAMA Oncol. 2020;6:1531–1532.
10. Desai A, et al. COVID-19 and cancer: a review of the registry-based pandemic response. JAMA Oncol. 2021. https://doi.org/10.1001/jamaoncol.2021.4083. Online ahead of print.
11. Roel E, et al. Characteristics and outcomes of over 300,000 patients with COVID-19 and history of cancer in the United States and Spain. Cancer Epidemiol Biomark Prev. 2021;30:1884–1894.
12. Pagano L, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021;14:168.
13. Blimark C, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100:107–113.
14. Teh BW, et al. Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. Br J Haematol. 2015;171:100–108.
15. Brioli A, et al. The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey. Ann Hematol. 2019;98:713–722.
16. Balmaceda N, et al. Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019. BMC Cancer. 2021;21:730.
17. Lim C, et al. Epidemiology and risks of infections in patients with multiple myeloma managed with new generation therapies. Clin Lymphoma Myeloma Leuk. 2021;21:444–450.e3.
18. Park H, et al. Infectious complications in multiple myeloma receiving autologous stem cell transplantation in the past 10 years. Int J Hematol. 2017;106:801–810.
19. Martinez-López J, et al. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. Blood Cancer J. 2020;101:1–11.
20. Chari A, et al. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020;136:3033–3040.
21. Engelhardt M, et al. Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany. Haematologica. 2020;105:2872–2878.
22. Dufour I, et al. COVID-19, impact on myeloma patients. Ann Hematol. 2020;0991–3.
23. Cook G, et al. Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. Br J Haematol. 2020;190:e83–e86.
24. Serra Mitjà P, Ávila M, García-Olivé I. Impacto de la pandemia por COVID-19 en el tratamiento del cáncer de pulmón. Med Clin (Barc). 2021. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3317217/.
25. Patt D, et al. Impact of COVID-19 on cancer care: how the pandemic is delaying cancer diagnosis and treatment for American seniors. JCO Clin Cancer Inf. 2020;4:1059–1071.
26. D’Silva K, et al. Outcomes of coronavirus disease 2019 infection among patients living with rheumatic diseases: a matched cohort study from a US multi-center research network. Arthritis Rheumatol. 2020;3:72 (suppl 10).
27. Hadi YB, Lakhani DA, Naqui SFZ, Singh S, Kupec JT. Outcomes of SARS-CoV-2 infection in patients with pulmonary sarcoidosis: a multicenter retrospective research network study. Resp Med. 2021;187:106538. Available from: https://www.resmedjournal.com/article/S0954-6111(21)00244-4/abstract.
28. London JW, Fazio-Eynullayeva E, Palchuk MB, Sankey P, McNair C. Effects of the COVID-19 pandemic on cancer care: how the pandemic is delaying cancer care and treatment for American seniors. JCO Clin Cancer Inf. 2020;4:657–665.
29. Khan A, et al. Impact of the coronavirus disease 2019 pandemic on gastro-intestinal procedures and cancers in the United States: a multicenter research network study. Gastroenterology. 2021;160:2602–2604.e5.
30. Raisisgani MG. Risk of complications in children with type 1 diabetes and Covid-19. J Endocrinol Soc. 2021;5:62–66.
31. Topalogul U, Palchuk MB. Using a federated network of real-world data to optimize clinical trials operations. JCO Clin Cancer Informatics. 2018;2:1–10.
32. Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic meta-analysis of randomized trials from 2015 to 2019. BMC Cancer. 2021;21:855.
33. Souza FSH, et al. On the analysis of mortality risk factors for hospitalized COVID-19 patients in the first 21 days of hospitalization: a multicenter retrospective study. JCO Clin Cancer Inf. 2021;13:e3084-3.
34. Williamson EJ, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–436.
35. Tempero M. COVID-19 and cancer: unintended consequences. J Natl Compr Canc Netw. 2020;18:1147.
36. Freer PE. The impact of the COVID-19 pandemic on breast imaging. Radio Clin North Am. 2021;59:1–11.
37. Roel E, et al. Cancer and the risk of COVID-19 diagnosis, hospitalisation, and death: a population-based multi-state cohort study including 4,618,377 adults in Catalonia, Spain. Int J Cancer. 2021. https://doi.org/10.1002/ijc.33846. Online ahead of print.
38. Ranganathan P, et al. Impact of COVID-19 on cancer care in India: a cohort study. Lancet Oncol. 2021;22:970–976.
39. Chen RC, Haynes K, Du S, Barron J, Katz AJ. Association of cancer screening deficit in the United States with the COVID-19 pandemic. JAMA Oncol. 2021;7:878–884.
40. Mato AR, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136:1134–1143.
41. Roosta Y, et al. Concurrent chronic lymphocytic leukemia and COVID-19: a comprehensive review of epidemiological, diagnostic, and therapeutic challenges. Leuk Res Rep. 2021;15:100239.
42. Buyuktas D, et al. COVID-19 infection in patients with acute leukemia; Istanbul experience. Am J Blood Res. 2021;11:427–437.
43. Fagundes EM, et al. Mortality by COVID-19 in adults with acute myeloid leukemia: a survey with hematologists in Brazil. Ann Hematol. 2021;1–3. https://doi.org/10.1007/s00277-02104659-0. Online ahead of print.
44. Bonifacio M, et al. The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population. Cancer Med. 2021;10:6310–6316.
45. Brecca M, et al. Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. Leukemia. 2020;34:2260–2261.
46. Claudiani S, et al. Prevalence of Sars-Cov-2 infection in patients with chronic myeloid leukemia. Blood. 2020;136:20.
47. Amador M, et al. Impact of the COVID-19 pandemic on the care of cancer patients in Spain. ESMO Open. 2021;100157. Available from: https://www.esmoopen.com/article/52059-7029(21)00117-4/fulltext.
48. Malard F, et al. Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Cancer J. 2021;11:142.
49. Maneikis K, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol. 2021;8:e583–e592.
50. Piñana JL, et al. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. Leuk Lymphoma. 2021;1:1–13. https://doi.org/10.1080/10428194.2021.1992619. Online ahead of print.
51. Lindemann M, et al. Humoral and cellular vaccination responses against SARS-CoV-2 in hematopoietic stem cell transplant recipients. Vaccines. 2021;9:1075.
52. Pagano L, et al. COVID-19 in vaccinated adult patients with hematological malignancies. Preliminary results from EPICOVDEHA. Blood. 2021. Available from: https://doi.org/10.1182/blood.2021014124.

ACKNOWLEDGEMENTS
This project was supported in part by CRIS contra el cancer foundation project and Trinetx.

AUTHOR CONTRIBUTIONS
Study design: JML, MP and GHI; Study investigators; Data analysis: GEI, DPR, LM and JML; Data interpretation: JML, RA, GHI, JSP, IZ, NLN, RI, CC, MC, RA, NGB, JP, RA1 and JdC; Manuscript preparation: JML, RA, GHI and JdC; Manuscript review and revisions: JML, RA, GHI and JdC; Final approval of manuscript: All authors.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to J. Martinez-Lopez.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021